Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 12/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8101344 | 0.92 | PTGS2 (0.58) | PTGS2PTGS1CNR1TP53SMN1; SMN2 | |
| SCHEMBL8776822 | 0.86 | PTGS2 (0.56) | PTGS2PTGS1CNR1CNR2 | |
| SCHEMBL8086011 | 0.83 | PTGS2 (0.59) | PTGS2PTGS1CNR1 | |
| SCHEMBL8087099 | 0.82 | PTGS2 (0.48) | PTGS2PTGS1CNR1 | |
| SCHEMBL8093419 | 0.82 | PTGS2 (0.72) | PTGS2PTGS1CNR1CNR2 | |
| SCHEMBL8094773 | 0.82 | PTGS2 (0.58) | PTGS2PTGS1CNR1CNR2 | |
| SCHEMBL8094547 | 0.81 | PTGS2 (0.60) | PTGS2PTGS1CNR1CNR2 | |
| SCHEMBL8086268 | 0.81 | PTGS2 (0.57) | PTGS2PTGS1CNR1 | |
| SCHEMBL8098696 | 0.80 | PTGS2 (0.47) | PTGS2PTGS1CNR1 | |
| SCHEMBL8086370 | 0.79 | PTGS2 (0.68) | PTGS2PTGS1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0808304-A1 | 2,3-SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024584-A1 | 2,3-SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-15 | — | — | WO | disclosed |